Lorna M. Maclean
Dundee, SCT, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Structure-activity relationships of 1,5-dihydro-2H-benzo[b][1,4]diazepine-2,4(3H)-diones as inhibitors of Trypanosoma cruzi.
Journal: RSC medicinal chemistry
Published: February 28, 2025
Pharmacological and structural understanding of the Trypanosoma cruzi proteasome provides key insights for developing site-specific inhibitors.
Journal: The Journal of biological chemistry
Published: May 22, 2024
Validation of Trypanosoma cruzi inactivation techniques for laboratory use.
Journal: PloS one
Published: December 22, 2023
Short-course combination treatment for experimental chronic Chagas disease.
Journal: Science translational medicine
Published: December 13, 2023
RES-Seq-a barcoded library of drug-resistant Leishmania donovani allowing rapid assessment of cross-resistance and relative fitness.
Journal: mBio
Published: November 06, 2023
Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome Inhibitors.
Journal: Journal of medicinal chemistry
Published: July 28, 2023
Identification of a potent and selective LAPTc inhibitor by RapidFire-Mass Spectrometry, with antichagasic activity.
Journal: PLoS neglected tropical diseases
Published: July 27, 2023
Author Correction: Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis.
Journal: Nature
Published: July 04, 2023
Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas' Disease.
Journal: Antimicrobial agents and chemotherapy
Published: October 04, 2021
Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis.
Journal: RSC medicinal chemistry
Published: June 12, 2020
The Qi Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani.
Journal: ACS infectious diseases
Published: January 23, 2020
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 10, 2019
Last Updated: 09/26/2026